GlassScriptPhysician profile
Richard John Wagner
NPI 1639794589
$4,700.68
in general payments reported to CMS, 2019-2025
23 companies · $2,564 in 2025
The $2,564 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.67 · 2022: $290 · 2023: $768 · 2024: $1,062 · 2025: $2,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,393.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $764.10 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $531.11 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $467.65 | 2022-2025 | Caplyta |
| Alkermes, INC. | $445.82 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $402.53 | 2023-2025 | Auvelity |
| Lundbeck LLC | $391.98 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $276.02 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $269.48 | 2024-2025 | Invega Sustenna |
| Corium, LLC | $246.47 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $173.51 | 2022-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $136.89 | 2024-2025 | Trintellix |
| Abbvie INC. | $136.08 | 2025 | |
| Neurocrine Biosciences, INC. | $126.89 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $94.45 | 2024-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $85.86 | 2022-2024 | Jornay Pm |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $28.08 | 2024 | |
| Tempus Ai, INC | $21.90 | 2024 | |
| Almatica Pharma LLC | $18.95 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.67 | 2023 | Quviviq |
| Acadia Pharmaceuticals INC | $17.11 | 2022 | |
| Merck Sharp & Dohme LLC | $16.67 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.38 | 2025 | Jornay Pm |
| Tris Pharma INC | $14.08 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.